Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Antitumor effect of zoledronic acid in asymptomatic biochemical relapse multiple myeloma (GEM/PETHEMA)
2009-017440-13Phase 4Active
- Sponsor
- Fundación PETHEMA
- Start
- Jan 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of zoledronic acid in multiple myeloma (MM) (2 arms), sponsored by Fundación PETHEMA. Primary endpoint: Time to next antitumor treatment. Started Jan 2010; status: active.
02
Drugs
zoledronic acid
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2009-017440-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-017440-13.